Oryzon Genomics SA (ORYN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Iadademstat, Gilteritinib Oral Tablet | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Phase I | Active Not Recruiting | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Sep 15, 2022 | ― |
| Vafidemstat | Borderline Personality Disorder | Phase II | Completed | Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population | Apr 12, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Iadademstat, Gilteritinib Oral Tablet | Phase I | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Active Not Recruiting | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Sep 15, 2022 | ― |
| Vafidemstat | Phase II | Borderline Personality Disorder | Completed | Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population | Apr 12, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oryzon Genomics (MX:ORYN) have in its pipeline
Oryzon Genomics SA MX:ORYN is currently developing the following drugs: Iadademstat, Gilteritinib Oral Tablet, Vafidemstat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.